Catalogue Search | MBRL
Are you sure you want to remove the book from the shelf?
{{itemTitle}}
27,278
result(s) for
"Brain Diseases Treatment."
Sort by:
The notebook of a new clinical neuropsychologist : stories from another world
\"Have you ever looked at a heavy volume on neuropsychology and wondered what it would actually be like to become a professional clinician, working every day with neurological patients in a busy hospital while simultaneously learning your craft? This book tells the story of that journey. a The Notebook of a New Clinical Neuropsychologist vividly details the experience of starting work in clinical neuropsychology, exploring early-career learning and development through an intimate, case-based approach. Topics include the learning of basic clinical skills and knowledge, counter-transference, the clinician's emotional experiences, ethical and moral dilemmas, and the development of clinical reasoning. The book is structured around individual studies from the author's early caseload, with each vignette containing the relevant neuropathology, clinical presentation, history, neuropsychological test finding and other clinical data. Chapters are also organized around key neuropathological conditions, including traumatic brain injury, stroke, and brain infections, which provide a broader context for the narrative focus of the book. A few academic books explore the personal, intellectual and ethical dilemmas that face a new clinician working with patients in a neuropsychological setting. Tailored to facilitate experiential learning via case studies, reflective practice and problem based-learning, the book will be of interest to students and professionals working within the broad area of neuropsychology and brain injury services.\"--Publisher description.
Book
Assistive technologies and other supports for people with brain impairment
Integrating current research with the experiences of people with cognitive disabilities, this volume examines how assistive and cognitive support technologies are being harnessed to provide assistance for thinking, remembering, and learning. The book vividly describes real-life situations in which cognitively impaired individuals use assistive supports and the advantages and limitations these individuals perceive from their use. It provides information on how cognitively impaired individuals and their families and caregivers can select the most appropriate technologies from a wide array of accommodations and resources, including individualized protocols of different forms of support to facilitate optimal functioning. The text offers practitioners a comprehensive and systematic process for ensuring their clients' effective application and utilization of this technology. This book will also provide insight for users of assistive technology and their families and caregivers to ensure optimal technology use.
eBook
The Alzheimer's solution : a breakthrough program to prevent and reverse the symptoms of cognitive decline at every age
\"Based on the largest clinical and observational study to date, neurologists and codirectors of the Brain Health and Alzheimer's Prevention Program at Loma Linda University Medical Center, Drs. Dean and Ayesha Sherzai, offer ... the first comprehensive program for preventing Alzheimer's disease and improving cognitive function\"-- Provided by publisher.
Book
The Percentage of Neutrophils is Independently Associated with Blood-Brain Barrier(BBB) Disruption in Myelin Oligodendrocyte Glycoprotein Antibody Associated Disease (MOGAD)
This study aims to investigate the risk factors associated with blood-brain barrier(BBB) disruption in patients with myelin oligodendrocyte glycoprotein antibody associated disease(MOGAD).
We collected clinical data from 95 patients diagnosed with MOGAD at the Department of Neurology, the First Affiliated Hospital of Zhengzhou University from October 2018 to May 2024. Patients were classified into normal or damaged BBB groups based on cerebrospinal fluid (CSF) albumin/serum albumin (QAlb). Binary logistic regression analysis was used to evaluate the risk factors for BBB disruption in MOGAD patients.
Our study revealed that in MOGAD patients with BBB damaged, there is a higher proportion of acute phase high EDSS scores, higher incidence of prodromal symptoms, and a higher rate of viral infections. Myelitis is the main clinical phenotype, with clinical manifestations primarily including limb weakness and bladder/bowel dysfunction. Laboratory tests showed higher levels of CSF protein, immunoglobulin (IgG), 24-hour intrathecal IgG synthesis rate, peripheral blood leukocytes, neutrophil percentage, NLR, anti-thyroglobulin antibodies(TGAbs), and fibrinogen levels, while free triiodothyronine (FT3) and lymphocyte percentage were lower. Multivariate regression analysis indicated that an increased neutrophil percentage is an independent risk factor for BBB damage in MOGAD patients (OR=1.068, 95% CI: 1.018-1.122, P=0.008).
Neutrophil percentage is a readily available and widely used indicator reflecting the immune system's state and the body's inflammation level. The change in neutrophil percentage is independently associated with BBB damage in MOGAD patients. This finding helps provide more reference information for personalized treatment decisions and further research into the pathogenesis of MOGAD.
Journal Article
Bitten : the secret history of lyme disease and biological weapons
\"A riveting thriller reminiscent of The Hot Zone, this true story dives into the mystery surrounding one of the most controversial and misdiagnosed conditions of our time--Lyme disease--and of Willy Burgdorfer, the man who discovered the microbe behind it, revealing his secret role in developing bug-borne biological weapons, and raising terrifying questions about the genesis of the epidemic of tick-borne diseases affecting millions of Americans today. While on vacation on Martha's Vineyard, Kris Newby was bitten by an unseen tick. That one bite changed her life forever, pulling her into the abyss of a devastating illness that took ten doctors to diagnose and years to recover: Newby had become one of the 300,000 Americans who are afflicted with Lyme disease each year. As a science writer, she was driven to understand why this disease is so misunderstood, and its patients so mistreated. This quest led her to Willy Burgdorfer, the Lyme microbe's discoverer, who revealed that he had developed bug-borne bioweapons during the Cold War, and believed that the Lyme epidemic was started by a military experiment gone wrong. In a superb, meticulous work of narrative journalism, Bitten takes readers on a journey to investigate these claims, from biological weapons facilities to interviews with biosecurity experts and microbiologists doing cutting-edge research, all the while uncovering darker truths about Willy. It also leads her to uncomfortable questions about why Lyme can be so difficult to both diagnose and treat, and why the government is so reluctant to classify chronic Lyme as a disease. A gripping, infectious page-turner, Bitten will shed a terrifying new light on an epidemic that is exacting an incalculable toll on us, upending much of what we believe we know about it\"-- Provided by publisher.
BOOK
Long-term Efficacy of Subthalamic Nucleus Deep Brain Stimulation in Parkinson＇s Disease： A 5-year Follow-up Study in China
Background： Subthalarnic nucleus deep brain stimulation （STN DBS） is effective against advanced Parkinson＇s disease （PD）, allowing dramatic improvement of Parkinsonism, in addition to a significant reduction in medication. Here we aimed to investigate the long-term effect of STN DBS in Chinese PD patients, which has not been thoroughly studied in China. Meihods： Ten PD patients were assessed before DBS and followed up 1, 3, and 5 years later using Unified Parkinson＇s Disease Rating Scale Part Ⅲ （UPDRS Ill）, Parkinson＇s Disease Questionnatire-39, Parkinson＇s Disease Sleep Scale-Chinese Version, Mini-mental State Examination, Montreal Cognitive Assessment, Hamilton Anxiety Scale and Hamilton Depression Scale. Stimulation parameters and drug dosages were recorded at each follow-up. Data were analyzed using the ANOVA for repeated measures. Resulis： In the ＂oft＂ state （off medication）, DBS improved UPDRS Ill scores by 35.87% in 5 years, compared with preoperative baseline （P 〈 0.001 ）. In the ＂on＂ state （on medication）, motor scores at 5 years were similar to the results of preoperative levodopa challenge test. The quality of life is improved by 58.18% （P 〈 0.001 ） from baseline to 3 years and gradually declined afterward. Sleep, cognition, and emotion were mostly unchanged. Levodopa equivalent daily dose was reduced from 660.4 ± 210.1 mg at baseline to 310.6 ± 158.4 mg at 5 years （by 52.96%, P 〈 0.001 ）. The average pulse width, frequency and amplitude at 5 years were 75.0 ± 18.21 Its, 138.5 ± 19.34 Hz, and 2.68 ± 0.43 V, respectively. Conclusions： STN DBS is an effective intervention for PD, although with other studies, patients in our study required lower voltage and associated with a slightly diminished efficacy after 5 years. Compared medication for satisfactory symptom control.
Journal Article
Advancing Brain Targeting: Cost-Effective Surface-Modified Nanoparticles for Faster Market Entry
Background/Objectives: The blood–brain barrier (BBB) poses a major obstacle to delivering therapeutic agents to the central nervous system (CNS), driving the need for innovative drug delivery strategies. Among these, nanoparticles (NPs) have gained attention due to their ability to enhance drug transport, improve bioavailability, and enable targeted delivery. Methods: This paper explores various surface modification strategies employed to optimize NP-mediated drug delivery across the BBB. Specifically, the functionalization of NPs with ligands such as transferrin (Tf), lactoferrin (Lf), protamine, and insulin is discussed, each demonstrating unique mechanisms for enhancing brain-targeting efficiency. In addition, this work provides a comprehensive overview of recent scientific advancements and market strategies aimed at accelerating the adoption of low-cost, surface-modified nanoparticles, ultimately improving patient access to effective CNS treatments. Conclusions: Preclinical and in vitro studies have demonstrated the effectiveness of these modifications in increasing drug retention and bioavailability in brain tissues. Additionally, while ligand-conjugated NPs hold significant promise for neuropharmacology, their clinical translation is often hindered by regulatory and economic constraints. Lengthy approval processes can slow market entry, but cost–benefit analyses indicate that surface-modified NPs remain financially viable, particularly as scalable manufacturing techniques and some ligands are cost-efficient.
Journal Article
Tenecteplase for Stroke at 4.5 to 24 Hours with Perfusion-Imaging Selection
Tenecteplase for thrombolysis in a 4.5-to-24-hour window did not improve disability outcomes at 90 days in patients with ischemic stroke who had been chosen on the basis of imaging. Most patients had endovascular thrombectomy.
Journal Article